A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

被引：0
作者：
Spurgeon, Stephen [1 ]
Chen, Andy I.
Okada, Craig [2 ]
Parekh, Samir [3 ]
Leshchenko, Violetta V. [3 ]
Palmbach, Gundula
Ratterree, Bashi
Subbiah, Nan
Capper, Christine [4 ]
Epner, Elliot M. [5 ]
机构：
[1] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Knight Canc Inst, Portland, OR 97201 USA
[2] OHSU Knight Canc Inst, Ctr Hematol Malignancies, Portland, OR USA
[3] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10467 USA
[4] Penn State Hershey Canc Inst, Hershey, PA USA
[5] Penn State Univ, Hershey Canc Ctr, Hershey, PA USA
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：203 / 203
页数：1
相关论文
共 50 条
  • [1] Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial
    Spurgeon, Stephen E.
    Sharma, Kamal
    Claxton, David F.
    Ehmann, Christopher W.
    Gallagher, Carla
    Shimko, Sara
    Stewart, August
    Parekh, Samir
    Leshchenko, Violetta V.
    Chen, Yiyi
    Epner, Elliot M.
    BLOOD, 2012, 120 (21)
  • [2] Targeting the epigenome: A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab in relapsed B-cell malignancies
    Spurgeon, S. E.
    Okada, C. Y.
    Huang, J.
    Phillips, J.
    Epner, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma
    Spurgeon, Stephen E.
    Sharma, Kamal
    Claxton, David F.
    Ehmann, Christopher
    Pu, Jeffrey
    Shimko, Sara
    Stewart, August
    Subbiah, Nan
    Palmbach, Gundula
    LeBlanc, Francis
    Latour, Emile
    Chen, YiYi
    Mori, Motomi
    Hasanali, Zainul
    Epner, Elliot M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (06) : 845 - 854
  • [4] Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189).
    Inwards, David James
    Hillman, David. W.
    Fishkin, Paul A.
    White, William L.
    Morton, Roscoe F.
    Dakhil, Shaker R.
    Nikcevich, Daniel A.
    Wender, Donald B.
    Fitch, Tom R.
    Kurtin, Paul J.
    BLOOD, 2006, 108 (11) : 777A - 777A
  • [5] Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin's Lymphoma and Previously Untreated Mantle Cell Lymphoma
    Spurgeon, Stephen
    Sharma, Kamal
    Claxton, David F.
    Ehmann, Christopher
    Shimko, Sara
    Stewart, August
    Parekh, Samir
    Leshchenko, Violetta V.
    Chen, Yiyi
    Mori, Motomi
    Pu, Jeffrey J.
    Epner, Elliot
    BLOOD, 2014, 124 (21)
  • [6] Phase II trial of cladribine (2-CDA) and rituximab in patients with CLL and SLL: Preliminary report of a single institution
    Bertazzoni, P.
    Laszlo, D.
    Gigli, F.
    Bassi, S.
    Calabrese, L.
    Saronni, L.
    Quama, J.
    Alietti, A.
    Cocorocchio, E.
    Martinelli, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 390 - 390
  • [7] Phase II trial of cladribine (2-CdA) and rituximab in patients with CLL and SLL: Preliminary report of a single institution
    Bertazzoni, P.
    Laszlo, D.
    Gigli, F.
    Bassi, S.
    Calabrese, L.
    Saronni, L.
    Quarna, J.
    Alietti, A.
    Cocorocchio, E.
    Martinelli, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] A randomised phase II study of fludarabine/cyclophosphamide +/-rituximab in patients with untreated mantle cell lymphoma
    Rule, S
    Burton, C
    Waleski, J
    Jack, A
    Seymour, J
    ANNALS OF ONCOLOGY, 2005, 16 : 95 - 95
  • [9] Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group
    Inwards, David J.
    Fishkin, Paul A. S.
    Hillman, David W.
    Brown, David W.
    Ansell, Stephen M.
    Kurtin, Paul J.
    Fonseca, Rafael
    Morton, Roscoe F.
    Veeder, Michael H.
    Witzig, Thomas E.
    CANCER, 2008, 113 (01) : 108 - 116
  • [10] Combination of Ibrutinib With Rituximab in Previously Untreated Older Patients With Mantle Cell Lymphoma-A Phase II Clinical Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 8 - 8
12345